Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYR | P14679 | 2/20 | 0.41 |
| ▸ | DAO | P14920 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.40 |
| ▸ | APP | P05067 | 5/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4140429 | 0.98 | TYR (0.39) | TYRDAOKDM4EPDPK1APP | |
| SCHEMBL10892930 | 0.83 | APP (0.40) | TYRDAOKDM4EAPPGAA | |
| SCHEMBL9049550 | 0.81 | APP (0.39) | TYRDAOAPPGAA | |
| SCHEMBL13422405 | 0.81 | DAO (0.45) | TYRDAOAPPGAAHCAR2 | |
| SCHEMBL3326691 | 0.77 | PDPK1 (0.39) | DAOPDPK1 | |
| SCHEMBL9012918 | 0.76 | APP (0.41) | TYRDAOKDM4EAPPGAA | |
| SCHEMBL9012854 | 0.74 | HTR2A (0.42) | APP | |
| SCHEMBL1584769 | 0.74 | DAO (0.53) | TYRDAOAPPHCAR2 | |
| SCHEMBL16231972 | 0.74 | APP (0.37) | TYRDAOKDM4EAPP | |
| SCHEMBL14478190 | 0.74 | APP (0.34) | TYRDAOKDM4EAPPGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5962480-A | CONTAINING PYRAN-4-ONE OR PYRID-4-ONE RING | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 1999-10-05 | — | — | US | claimed |
| US-20250186381-A1 | ARTIFICIAL OXYGEN CARRIER BLOOD PRODUCT | DANESH ANDRE (US) | 2025-06-12 | — | — | US | disclosed |
| US-20250064771-A1 | ARTIFICIAL OXYGEN CARRIER BLOOD PRODUCT | DANESH ANDRE (US) | 2025-02-27 | — | — | US | disclosed |
| US-20250064942-A1 | ARTIFICIAL OXYGEN CARRIER BLOOD PRODUCT | DANESH ANDRE (US) | 2025-02-27 | — | — | US | disclosed |
| US-20240343679-A1 | Artificial oxygen carrier blood product | DANESH ANDRE (US) | 2024-10-17 | — | — | US | disclosed |
| EP-2906216-B1 | INHIBITORS OF DNA GYRASE FOR THE TREATMENT OF BACTERIAL INFECTIONS | KUMAR AJAY (GB) | 2020-06-24 | — | — | EP | disclosed |
| US-9643979-B2 | Inhibitors of DNA gyrase for the treatment of bacterial infections | VITAS PHARMA RESEARCH PRIVATE LIMITED (IN) | 2017-05-09 | — | — | US | disclosed |
| CN-104529885-B | Has multiple bioactive pyridone ketone derivatives and application thereof | 浙江工商大学 | 2016-06-22 | — | — | CN | disclosed |
| US-20150284408-A1 | INHIBITORS OF DNA GYRASE FOR THE TREATMENT OF BACTERIAL INFECTIONS | KUMAR, AJAY, DR. (GB) | 2015-10-08 | — | — | US | disclosed |
| EP-2906216-A2 | INHIBITORS OF DNA GYRASE FOR THE TREATMENT OF BACTERIAL INFECTIONS | Vitas Pharma Research Private Limited (IN) | 2015-08-19 | — | — | EP | disclosed |
| US-20090198063-A1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-08-06 | — | — | US | disclosed |
| US-20090198063-A1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-08-06 | — | — | US | disclosed |
| EP-2022793-A1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-02-11 | — | — | EP | disclosed |
| US-6232340-B1 | HYDROXYOXOVANADIUM, MU-OXO DIMERIC OXOVANADIUM AND CIS-DIOXOVANADIUM COMPLEXES, ARE ANTI-PROLIFERATIVE AND/OR ANTI-METASTATIC AGENTS TO TREAT DIABETES, ARTHRITIS, MULTIPLE SCLEROSIS, PSORIASIS AND LUPUS | ANGIOTECH PHARMACEUTICALS, INC. (CA) | 2001-05-15 | — | — | US | disclosed |
| EP-0984971-A1 | VANADIUM COMPLEXES AND DERIVATIVES THEREOF AND METHODS RELATED THERETO | Angiotech Pharmaceuticals, Inc. (CA) | 2000-03-15 | — | — | EP | disclosed |
| US-5962480-A | CONTAINING PYRAN-4-ONE OR PYRID-4-ONE RING | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 1999-10-05 | — | — | US | disclosed |
| WO-1998049173-A1 | VANADIUM COMPLEXES AND DERIVATIVES THEREOF AND METHODS RELATED THERETO | ANGIOTECH PHARMACEUTICALS, INC. (CA) | 1998-11-05 | — | — | WO | disclosed |
| EP-0838220-A1 | DRUG FOR AMELIORATING BRAIN DISEASES | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 1998-04-29 | — | — | EP | disclosed |
| EP-0594585-A1 | IRON ASSAY | BRITISH TECHNOLOGY GROUP LTD (GB) | 1994-05-04 | — | — | EP | disclosed |
| WO-1991011720-A1 | IRON ASSAY | BRITISH TECHNOLOGY GROUP LTD (GB) | 1991-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240343679-A1 | Artificial oxygen carrier blood product | TFRC, HBB, HBG2 | TYR 503/4885DAO 98/4885KDM4E 2415/4885 |
| US-20250186381-A1 | ARTIFICIAL OXYGEN CARRIER BLOOD PRODUCT | TFRC, FTH1, HBB | TYR 304/4885DAO 39/4885KDM4E 3898/4885 |
| US-20250064771-A1 | ARTIFICIAL OXYGEN CARRIER BLOOD PRODUCT | HBB, HBG2, TFRC | TYR 257/4885DAO 34/4885KDM4E 3900/4885 |
| US-20150284408-A1 | INHIBITORS OF DNA GYRASE FOR THE TREATMENT OF BACTERIAL INFECTIONS | TOP1, TOP2A, DNASE1 | TYR 4216/4885DAO 1110/4885KDM4E 2901/4885 |
| US-20250064942-A1 | ARTIFICIAL OXYGEN CARRIER BLOOD PRODUCT | HBB, HBG2, TFRC | TYR 240/4885DAO 36/4885KDM4E 3919/4885 |
| US-20090198063-A1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | IKZF3, ZC3HAV1L, H1-4 | TYR 179/4885DAO 658/4885KDM4E 1732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.